Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RadioPARP: Olaparib with Radiation in TNBC
NCT03109080Phase 1Completed
- Sponsor
- Institut Curie
- Start
- Jul 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in triple-negative breast cancer (TNBC), sponsored by Institut Curie. Primary endpoint: Maximal Tolerated Dose at 2 years. Started Jul 2017; status: completed.
02
Drugs
olaparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03109080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109080.